Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition
Yiannis Drosos, Jacquelyn A. Myers, Beisi Xu, et al.
Molecular Cell (2022) Vol. 82, Iss. 13, pp. 2472-2489.e8
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Pharmacological targeting of the cancer epigenome
Nathaniel W. Mabe, Jennifer A. Perry, Clare F. Malone, et al.
Nature Cancer (2024) Vol. 5, Iss. 6, pp. 844-865
Closed Access | Times Cited: 19
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy
Yaniv Kazansky, Daniel Cameron, Helen S. Mueller, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 965-981
Open Access | Times Cited: 18
Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNF
Sandi Radko-Juettner, Hong Yue, Jacquelyn A. Myers, et al.
Nature (2024) Vol. 628, Iss. 8007, pp. 442-449
Closed Access | Times Cited: 18
The Role of SWI/SNF Complex in Bladder Cancer
Zhenlain Lei, Yanfeng Han, John B. Liao, et al.
Journal of Cellular and Molecular Medicine (2025) Vol. 29, Iss. 1
Open Access | Times Cited: 2
Chromatin remodellers as therapeutic targets
Hayden A. Malone, Charles W.M. Roberts
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 9, pp. 661-681
Closed Access | Times Cited: 11
Hallmark discoveries in the biology of non-Wilms tumour childhood kidney cancers
Daniela Perotti, Maureen J. O’Sullivan, Amy L. Walz, et al.
Nature Reviews Urology (2025)
Closed Access | Times Cited: 1
Chromatin regulation of transcriptional enhancers and cell fate by the Sotos syndrome gene NSD1
Zhen Sun, Yuan Lin, Mohammed T. Islam, et al.
Molecular Cell (2023) Vol. 83, Iss. 14, pp. 2398-2416.e12
Open Access | Times Cited: 18
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes
Varadha Balaji Venkadakrishnan, Adam G. Presser, Richa Singh, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis
Abhijit Parolia, Sanjana Eyunni, Brijesh Kumar Verma, et al.
Nature Genetics (2024)
Open Access | Times Cited: 6
(mis)-Targeting of SWI/SNF complex(es) in cancer
Divya Reddy, Saikat Bhattacharya, Jerry L. Workman
Cancer and Metastasis Reviews (2023) Vol. 42, Iss. 2, pp. 455-470
Open Access | Times Cited: 16
Epigenetic reprogramming in pediatric gliomas: from molecular mechanisms to therapeutic implications
Santiago Haase, Stephen V. Carney, María L. Varela, et al.
Trends in cancer (2024) Vol. 10, Iss. 12, pp. 1147-1160
Closed Access | Times Cited: 5
Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges
Sarah Gold, Ali Shilatifard
Journal of Clinical Investigation (2024) Vol. 134, Iss. 20
Open Access | Times Cited: 5
Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors
Cinzia Lanzi, Noemi Arrighetti, Sandro Pasquali, et al.
Biochemical Pharmacology (2023) Vol. 215, pp. 115727-115727
Closed Access | Times Cited: 12
Preclinical Anticipation of On- and Off-Target Resistance Mechanisms to Anti-Cancer Drugs: A Systematic Review
Paulina J. Dziubańska-Kusibab, Ekaterina Nevedomskaya, Bernard Haendler
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 705-705
Open Access | Times Cited: 4
Challenges and opportunities in targeting epigenetic mechanisms for pulmonary arterial hypertension treatment
Jie Feng, Yunman Liu, Kai Li, et al.
International Journal of Pharmaceutics (2025) Vol. 672, pp. 125332-125332
Closed Access
Role of epigenetics in paediatric cancer pathogenesis & drug resistance
Jia Yu Leung, Hsin Yao Chiu, Reshma Taneja
British Journal of Cancer (2025)
Closed Access
The Sotos syndrome gene Nsd1 safeguards developmental gene enhancers poised for transcription by maintaining the precise deposition of histone methylation
Jie Li, Zhucui Li, Jiekai Yin, et al.
Journal of Biological Chemistry (2025), pp. 108423-108423
Open Access
The genetic basis of human height
Louise S. Bicknell, Joel N. Hirschhorn, Ravi Savarirayan
Nature Reviews Genetics (2025)
Closed Access
Rapid and robust validation of pooled CRISPR knockout screens using CelFi
Allister J. Loughran, Shilpa Narina, Jonathon Klein, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis
Abhijit Parolia, Sanjana Eyunni, Brijesh Kumar Verma, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 3
Targeting KDM2A Enhances T-cell Infiltration in NSD1-Deficient Head and Neck Squamous Cell Carcinoma
Chen Chen, June Ho Shin, Zhuoqing Fang, et al.
Cancer Research (2023) Vol. 83, Iss. 16, pp. 2645-2655
Open Access | Times Cited: 6
Nuclear envelope, chromatin organizers, histones, and DNA: The many achilles heels exploited across cancers
A. K. Balaji, Santam Saha, Shruti Deshpande, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 9
The epigenome and the many facets of cancer drug tolerance
Paul C. Moore, Kurt W. Henderson, Marie Classon
Advances in cancer research (2023), pp. 1-39
Closed Access | Times Cited: 5
Epigenetic Causes of Overgrowth Syndromes
Julian C. Lui, Jeffrey Baron
The Journal of Clinical Endocrinology & Metabolism (2023) Vol. 109, Iss. 2, pp. 312-320
Open Access | Times Cited: 5
Translational Aspects of Epithelioid Sarcoma: Current Consensus
Thomas G. P. Grünewald, Sophie Postel‐Vinay, Robert Nakayama, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 6, pp. 1079-1092
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top